Outside in - inside out. Creating focus on the patient - a vaccine company perspective

Hum Vaccin Immunother. 2018 Jun 3;14(6):1509-1514. doi: 10.1080/21645515.2018.1428510. Epub 2018 Feb 15.

Abstract

Involving patients in the development of medicines and vaccines should result in benefits to patients. The vaccine recipient is usually a healthy person. We describe the rationale and implementation of a vaccine company's initiative to encourage employees to identify with patients of the conditions prevented by the vaccines they help to produce. The Voice of the Patient ("VoP"), begun in 2014, is an educational programme directed at the 16,000 employees of a global vaccine company. It engages employees through an understanding that they are all "vaccine patients", and that they can make a difference by considering the impact of decisions made in their day to day work. The initiative includes presentations about vaccine-preventable diseases, global live webcasts with experts and patients, employee visits to healthcare facilities in developing countries, and the production of patient-focused sections in research publications. In a 2017 employee survey, 90% of respondents said they know how their daily work impacts patients and they demonstrate focus on patients. We believe this is preliminary evidence that, by supporting employee awareness of the impact of their individual roles, VoP could be a model for a type of initiative that will contribute to industry's continuing evolution towards more patient-centred healthcare.

Keywords: Patient centered; patient engagement; patient focus; pharmaceutical industry; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Transmission, Infectious / prevention & control*
  • Drug Development / methods*
  • Humans
  • Patient Participation*
  • Vaccines / administration & dosage*
  • Vaccines / immunology*

Substances

  • Vaccines

Grants and funding

All costs related to the development of this manuscript were met by GSK Biologicals SA.